ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/N2-((1S)-1-carboxy-3-cyclohexylpropyl)-L-lysyl-L-proline
C21H37N3O5
411.5 g/mol
APIDanger

Lisinopril specified impurity F

CAS1132650-67-9EC643-030-5
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

Lisinopril specified impurity F is a reference standard used in pharmaceutical analysis. It is a chemically defined compound related to the active pharmaceutical ingredient lisinopril, serving as a quality control tool for impurity profiling.

pharmaceutical impurity reference standardquality control in pharmaceutical manufacturing

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Lisinopril specified impurity F?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ReferenceSame Category

(1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)-2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione

CAS1132654-54-6

pharmaceutical raw material

ReferenceSame Category

5'-Deoxy-5-fluoro-N-{[(²H₁₁)pentyloxy]carbonyl}cytidine

CAS1132662-08-8

pharmaceutical raw material

ReferenceSame Category

N-[(1R)-1-Borono-3-methylbutyl]-Nalpha-(pyrazine-2-carbonyl)-D-phenylalaninamide

CAS1132709-15-9

pharmaceutical raw material

ReferenceSame Category

Hirudin

CAS113274-56-9

pharmaceutical raw material

Referencesame scaffold

(2S)-1-((2S)-2-(((1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl)amino)propanoyl)pyrrolidine-2-carboxylic acid

CAS2055735-10-7

research compound

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more

Safety Reference

Harmful
Harmful
Health Hazard
Health Hazard
Danger
H319Causes serious eye irritation
H360May damage fertility or the unborn child
Identifiers
IUPAC Name

(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-cyclohexylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid

InChIKey

QYSKCMYFYQRFSL-BZSNNMDCSA-N

SMILES

C1CCC(CC1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)O

Synonyms (10)
  • LISINOPRIL IMPURITY F (EP IMPURITY)
  • Lisinopril EP Impurity F
  • Lisinopril Imp. F (EP); (2S)-1-[(2S)-6-Amino-2-[[(1S)-1-carboxy-3-cyclohexylpropyl]amino]hexanoyl]-pyrrolidine-2-carboxylic Acid; Lisinopril Cyclohexyl Analogue; N2-[(1S)-1-carboxy-3-cyclohexylpropyl]-L-lysyl-L-Proline
  • LISINOPRIL IMPURITY F
  • Lisinopril impurity F CRS

Sourcing Lisinopril specified impurity F?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→